Navigation Links
CEO's Letter to Shareholders of Imaging Diagnostic Systems, Inc.
Date:8/5/2008

izing the CTLM(R) in late 2002, we sold our first CTLM(R) system in January 2003. Since that sale, we sold 12 additional units. There are CTLM(R) systems sold or in clinical collaboration programs currently in China, Italy, Poland, Czech Republic, United Arab Emirates, and Malaysia. Our end users and clinical collaboration partners worldwide have completed more than 13,000 clinical scans. We have deposits for the purchase of CTLM(R) systems from our distributors in Hong Kong and Turkey; and our Director of Global Marketing is working with our distributors to bring their earnest leads to sale before the end of the year. We anticipate the sale of eight CTLM(R) systems before the end of the year in China, Italy, and the United Arab Emirates.

Our stock price has also faced challenges over the past several years as the Company evolved to establish itself on the market. IDSI is an equity-funded Company. Since inception, substantially all of our necessary funding came from the proceeds of the sale of common stock, convertible preferred stock and convertible debentures. The convertible securities were all converted into common stock. In essence, our common stock is our currency and since January 2001 we have used a series of private equity credit agreements with Charlton Avenue, LLC, an institutional investor, to raise the capital necessary to fund the Company's operations. The use of private equity credit agreements is dilutive as the investor sells our shares into the market.

Cost cutting initiatives and staff reductions were initiated in April by the time I was appointed Interim CEO and Chairman of the Board. I met with Executive Management and we made the decision to terminate our lease pursuant to the six-month notice provision and to lease a smaller facility. Our current facility is 24,000 sq/ft with a base rent of $24,000 per month plus insurance, taxes and maintenance, which we estimate to be $9,440 per month for a total monthly cost of $33,440. Our ne
'/>"/>

SOURCE Imaging Diagnostic Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
2. Three CEOs and University President Named Winners of Greater Baltimore Committees 2008 Baltimore Region Bioscience Awards
3. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
4. Survey Sees Mass. CEOs as Bullish on Own Businesses
5. Alfacell Receives NASDAQ Delisting Letter
6. Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd.
7. Eisai Receives Action Letter on Fospropofol Disodium Injection for Sedation in Diagnostic or Therapeutic Procedures
8. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
9. Spherix Receives NASDAQ Bid Price Deficiency Letter
10. Favrille Announces Receipt of Nasdaq Letters
11. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... USA, and Cardiff, UK (PRWEB) January 13, 2014 ... technology development leader with more than 20 years in ... for optics and photonics . Hainsey will serve as ... delighted to have Dr. Hainsey join SPIE as our ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... MAISONS-ALFORT, France, April 14 /PRNewswire-FirstCall/,-- Cephalon, Inc. (Nasdaq: ... has granted marketing authorization for EFFENTORA(TM), a buccal,tablet ... treatment of,breakthrough cancer pain (BTCP) in adult patients ... pain. The approval allows Cephalon,to market EFFENTORA in ...
... blood-based ColonSentry(TM) test -, TORONTO, April 14 ... on developing blood-based biomarker tests for the early,detection ... performance results from a large validation study of ... patient,s current risk for,colorectal cancer. This panel forms ...
... ImaRx Therapeutics,Inc. (Nasdaq: IMRX ) today announced ... 11, 2008 indicating that for the last 30,consecutive business ... closed,below $1.00 per share. As a result, the company ... continued listing set forth in,Marketplace Rule 4310(c)(4)., In ...
Cached Biology Technology:Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 2Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 3Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 3ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQ's Minimum Bid Price Requirement 2
(Date:4/17/2014)... 2014The development of stem cell therapies to cure a ... stem cell populations based on cell surface markers. Researchers ... marker that is highly expressed in a type of ... they describe in an article in BioResearch Open ... Inc., publishers. The article is available free on the ...
(Date:4/17/2014)... cartridge developed at Sandia National Laboratories and recently licensed ... and cheaper. , Bacillus anthracis , the ... all over the world and can cause serious, and ... bacteria can survive in harsh conditions for decades. In ... through skin contact, inhalation of spores or eating contaminated ...
(Date:4/17/2014)... to produce hydrogen sulfide in order to properly multiply ... from the Center for Craniofacial Molecular Biology at the ... Songtao Shi, principal investigator on the project, said the ... the flow of calcium ions. The essential ions activate ... or the creation of new bone tissue, and keeps ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... 9, 2009 A nutritionist whose research was instrumental in ... Children (WIC) food subsidy will receive the March of Dimes ... maternal-fetal nutrition. Gail Harrison, Ph.D., MNS, , ... the University of California, Los Angeles School of Public Health, ...
... 150th anniversary this month of the publication of On ... Sciences (AIBS) is publishing open access two peer-reviewed articles ... , The two articles are by Kevin Padian of ... of Western Carolina University. Padian,s article, "Ten Myths About ...
... Conn.Researchers at Yale University have developed synthetic molecules capable ... HIV-infected cells, as well as to prostate cancer cells. ... the American Chemical Society , could lead to novel ... called "antibody-recruiting molecule targeting HIV" (ARM-H) and "antibody-recruiting ...
Cached Biology News:March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2New synthetic molecules trigger immune response to HIV and prostate cancer 2
... Science, which pioneered the blending of thermostable ... and Expand Long Template PCR Systems, now ... the first product of a family ... blend combines Taq DNA Polymerase with a ...
The HEPTEST assays provide a sensitive, simple, rapid, and convenient in vitro quantitation of heparin, low molecular weight heparins, and heparinoids in plasma and whole blood. Sample Type: wh...
...
... enzyme mix (Thermoprime Plus DNA Polymerase with ... four times higher fidelity than standard Taq ... Taq DNA polymerase, Amplifies DNA templates >20kb, ... PCR, PCR for cloning and mutagenesis We ...
Biology Products: